Findings

What do systematic reviews say?

2,234 questions · 2,325 findings · 216 reviews · Airways

Sort:Best matchNewestHighest certainty Download CSV

No studies found 249 · 10.7%GRADE not reported 107 · 4.6%Very low 276 · 11.9%Low 751 · 32.3%Moderate 718 · 30.9%High 224 · 9.6%

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

PAP · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

RAP · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

Cardiac index · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

PVR · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Low

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

Improvement in WHO functional class · people with pulmonary hypertension due to left‐heart disease

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i probably leads to lower improvement in WHO functional class compared with placebo (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 0.53 [0.32, 0.87]
3 studies · 285 participants
Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

Six‐minute walk distance · people with pulmonary hypertension due to left‐heart disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 284 participants
Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

All‐cause mortality · people with pulmonary hypertension due to left‐heart disease

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i showed no clear difference in mortality compared with placebo (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 1.27 [0.28, 5.8]
3 studies · 286 participants
Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

Quality of life · people with pulmonary hypertension due to left‐heart disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 52 participants
Low

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

PAP · people with pulmonary hypertension due to left‐heart disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 130 participants
Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

Cardiac index · people with pulmonary hypertension due to left‐heart disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 96 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

All‐cause mortality · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i leads to lower mortality compared with placebo (high certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 0.22 [0.07, 0.68]
8 studies · 1119 participants
High

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

Improvement in WHO functional class · people with pulmonary hypertension due to lung disease

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i may leads to higher improvement in WHO functional class compared with placebo (low certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 44.33 [4.78, 410.94]
1 study · 40 participants
Low

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

Six‐minute walk distance · people with pulmonary hypertension due to lung disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 350 participants
High

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

All‐cause mortality · people with pulmonary hypertension due to lung disease

The review found no eligible studies for this question.

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

Quality of life · people with pulmonary hypertension due to lung disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 238 participants
Moderate

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

PAP · people with pulmonary hypertension due to lung disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 61 participants
Moderate

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

Cardiac index · people with pulmonary hypertension due to lung disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

PVR · people with pulmonary hypertension due to lung disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

RAP · people with pulmonary hypertension due to lung disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Improvement in WHO functional class · people with pulmonary hypertension due to CTEPH

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo (low certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 17.18 [0.78, 380.84]
1 study · 19 participants
Low